Welcome to our dedicated page for Alr Technologies SEC filings (Ticker: ALRTF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ALR Technologies SG Ltd. files as a foreign private issuer, and its regulatory documents describe a Singapore-based diabetes management company with ordinary shares traded under ALRTF. The filing record includes Form 6-K current reports, interim consolidated financial statements, management discussion and analysis, controls and procedures, risk factors, legal proceedings, market-risk disclosure, and exhibits tied to company announcements.
Company-specific disclosures cover the GluCurve Pet CGM business, diabetes data-management technology, operating losses and shareholders’ deficit, ordinary-share capital structure, and warrant modifications. The filings also document board and executive-related warrant holdings where those securities are amended or reported in material-event filings.
ALR Technologies SG Ltd. filed a report as a foreign private issuer to share a recent company announcement. The filing states that on December 8, 2025, the company issued a press release, which is attached to the report as Exhibit 99.1.
The press release announced the relaunch of the company’s GluCurve Pet CGM, a continuous glucose monitoring product for pets. This report mainly serves to make that product update publicly available to investors through the SEC’s disclosure system.